# Calcium channel blockers

Drug · id `cardio:calcium-channel-blockers` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Calcium channel blocker; Calcium antagonists

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease  

## In plain language

A class of medicines that work by blocking calcium from moving into cells. The US label read for one calcium channel blocker says it may be used alone or with other blood pressure and angina medicines. It lists high blood pressure, and coronary artery disease in the forms chronic stable angina, vasospastic angina and angiographically documented disease in people without heart failure or an ejection fraction under 40%.

## Technical summary

Class page. MeSH descriptor D002121 (Calcium Channel Blockers, last updated 2020-05-27) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name amlodipine besylate tablet (application NDA019787, effective 2023-02-15 in openFDA). The label describes amlodipine as a dihydropyridine calcium antagonist, so it does not stand for every member of the class. The label text read states no age range for its uses. This page gives no dose, no trial result and no guideline statement, and none of the label's warnings or interactions was recorded. Medicines of the class that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with hypertension, and patients with chronic stable angina, vasospastic angina, or angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with hypertension, and patients with chronic stable angina, vasospastic angina, or angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227367289c-b0b0-466a-83e2-558e2985c29f%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:36Z. Source state: Current. Version fingerprint: bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d.
     How it applies: The label sentences that call the medicine a calcium channel blocker and list hypertension and coronary artery disease.
  2. Background: openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227367289c-b0b0-466a-83e2-558e2985c29f%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:36Z. Source state: Current. Version fingerprint: bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d.
     How it applies: Effective date of the label text read, 20230215.
  3. Supports: MeSH scope note for descriptor D002121 (Calcium Channel Blockers) (Dataset, edition MeSH linked-data record of the preferred concept M0003165 of descriptor D002121, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0003165>
     Locator: scopeNote.@value. Retrieved 2026-10-30T19:49:57Z. Source state: Current. Version fingerprint: afa580433e9343662dc0028eebedb5b1943e77b266b29033c5597b5175cd8379.
     How it applies: MeSH scope note: what the class does.

## Connected pages

- A US label lists treating high blood pressure as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-norvasc-label-indications` and its context]
- A US label lists coronary artery disease as an indication: Coronary artery disease (`cardio:coronary-artery-disease`) [a claim, not a settled fact; see claim `cardio:claim-fda-norvasc-label-indications` and its context]
- A US label lists chronic stable angina as an indication: Stable angina (`cardio:stable-angina`) [a claim, not a settled fact; see claim `cardio:claim-fda-norvasc-label-indications` and its context]
- Record on resistant high blood pressure that names this class; a US label of the class lists high blood pressure: Resistant hypertension (`cardio:resistant-hypertension`)
- Reading path on high blood pressure that names this class; a US label of the class lists high blood pressure: From a high blood pressure reading to stroke prevention (`cardio:reading-path-high-bp`)
- Patient guide on high blood pressure that names this class; a US label of the class lists high blood pressure: Newly diagnosed high blood pressure (`cardio:guide-new-high-blood-pressure`)
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Amlodipine (`cardio:amlodipine`)
- Related to: Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- Has subtype: Diltiazem (`cardio:diltiazem`)
- Has subtype: Nifedipine (`cardio:nifedipine`)
- Related to: Ranolazine (`cardio:ranolazine`)
- Has subtype: Verapamil (`cardio:verapamil`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 11 registry trials

## Provenance

Content hash: 38fb7af65e3e3a53a1e86e71ecc6efa6ab3eed1f5c4b7cf4d61b0000cabf9f16
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
